When does Opdivo’s patent expire?
Opdivo (nivolumab) patent expiration depends on which specific patent is being considered (drug composition, formulations, methods of use, or related manufacturing/intellectual-property rights). Multiple patents can be filed and expire in different years, so there is no single universal expiration date for “the Opdivo patent.”
Which Opdivo patents are most relevant to exclusivity and biosimilar timing?
For biologics like Opdivo, market entry timing is usually driven by a mix of:
- Patent expirations tied to key claims, and
- Regulatory exclusivity that can delay biosimilar competition even after some patents expire.
To identify the relevant expiration dates tied to specific Opdivo patents, DrugPatentWatch.com tracks listed patents and their estimated expiration windows for Opdivo. You can check: DrugPatentWatch.com: Opdivo (nivolumab) patent expiration.
Are there different expiration dates by country (US vs EU)?
Yes. Patent terms and the timing of any exclusivity (and how they apply) vary by jurisdiction. If you’re looking for an operational date (when biosimilar entry could become more feasible), you typically need to check the relevant patents and regulatory protections for the country or region you care about.
Does Opdivo’s “last patent” determine when competitors can launch?
Not always. Even after one patent expires, another Opdivo patent may still block entry, and exclusivity can also delay competition. Competitors (including biosimilar applicants) often focus on:
- Which listed patents they must address, and
- When those patents expire or are weakened through litigation or settlement.
How can I find the exact Opdivo expiration date I need?
The most direct approach is to look up the specific Opdivo patent family you care about (or use a tracker that lists them). Start with the patent-by-patent listings on DrugPatentWatch.com, then match the patent claims to what biosimilar applicants would need to challenge or wait out: DrugPatentWatch.com: Opdivo (nivolumab) patent expiration.
Sources
- DrugPatentWatch.com: Opdivo (nivolumab) patent expiration